Latest News and Press Releases

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~ ~...

~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized,...

~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~ ~ Fennec HEARS™ Program Offers Comprehensive Patient...

~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of...

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ...

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access...

~ PEDMARKTM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ Commercial Team Built Out In Anticipation of U.S. Launch of PEDMARKTM ~ ~ Recently Announced...

~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to...

RESEARCH TRIANGLE PARK, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...

RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...